tiprankstipranks
Advertisement
Advertisement

HK:2511 Stock Latest News

HighTide Therapeutics Highlights HTD1801’s Potential as Foundational CKM Therapy in 2025 Results
Company AnnouncementsHighTide Therapeutics Highlights HTD1801’s Potential as Foundational CKM Therapy in 2025 Results
8d ago
2511
HighTide positions HTD1801 as potential foundational therapy for CKM diseases
PremiumCompany Announcements
HighTide positions HTD1801 as potential foundational therapy for CKM diseases
11d ago
2511
HighTide Therapeutics Sets March 27 Board Meeting to Approve 2025 Annual Results
PremiumCompany Announcements
HighTide Therapeutics Sets March 27 Board Meeting to Approve 2025 Annual Results
25d ago
2511
HighTide’s First NDA for Diabetes Drug HTD1801 Accepted by China’s NMPA
PremiumCompany Announcements
HighTide’s First NDA for Diabetes Drug HTD1801 Accepted by China’s NMPA
28d ago
2511
HighTide Flags Trial Quality Issues After Completing Phase IIb MASH Study of HTD1801
PremiumCompany Announcements
HighTide Flags Trial Quality Issues After Completing Phase IIb MASH Study of HTD1801
2M ago
2511
HighTide Therapeutics Names Veteran Cardiometabolic Leader Filip Surmont as Chief Medical Officer
PremiumCompany AnnouncementsHighTide Therapeutics Names Veteran Cardiometabolic Leader Filip Surmont as Chief Medical Officer
2M ago
2511
HighTide Therapeutics Sets Up Nomination Committee to Bolster Governance
Premium
Company Announcements
HighTide Therapeutics Sets Up Nomination Committee to Bolster Governance
3M ago
2511
HighTide Therapeutics’ HTD1801 Outperforms in Phase III Trial
Premium
Company Announcements
HighTide Therapeutics’ HTD1801 Outperforms in Phase III Trial
4M ago
2511
HighTide Therapeutics Showcases Renal Benefits of HTD1801 at ASN Meeting
PremiumCompany Announcements
HighTide Therapeutics Showcases Renal Benefits of HTD1801 at ASN Meeting
5M ago
2511
HighTide Therapeutics Reports Positive Phase III Results for HTD1801 in Diabetes Treatment
PremiumCompany Announcements
HighTide Therapeutics Reports Positive Phase III Results for HTD1801 in Diabetes Treatment
5M ago
2511
PremiumCompany Announcements
HighTide Therapeutics Reports Promising Interim Results for 2025
8M ago
2511
PremiumCompany Announcements
HighTide Therapeutics Partners with Chinese Academy for Metabolic Disease Research
8M ago
2511
PremiumCompany AnnouncementsHighTide Therapeutics to Review Interim Financial Results
8M ago
2511
Premium
Company Announcements
HighTide Therapeutics Completes Successful Share Placement
9M ago
2511
Premium
Company Announcements
HighTide Therapeutics Announces Unanimous Approval of AGM Resolutions
9M ago
2511
PremiumCompany Announcements
Hightide Therapeutics Announces New Share Placement to Fund Lead Compound Development
10M ago
2511
PremiumCompany Announcements
HighTide Therapeutics Announces Annual General Meeting and Key Resolutions
10M ago
2511
PremiumCompany Announcements
HighTide Therapeutics’ HTD1801 Shows Promising Results in Phase 3 Trials for Type 2 Diabetes
12M ago
2511
PremiumCompany Announcements
HighTide Therapeutics Reports Promising 2024 Results with Core Product HTD1801
1y ago
2511
PremiumCompany AnnouncementsHighTide Therapeutics Schedules Board Meeting for Annual Results Approval
1y ago
2511
Premium
Company Announcements
HighTide Completes Enrollment for Diabetes Drug Trial
1y ago
2511
Premium
Company Announcements
HighTide Therapeutics Appoints New Joint Company Secretary
1y ago
2511

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >